These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2007-003369-42 Etude de phase II randomisée, multicentrique, en ouvert, évaluant l'efficacité de l’association Avastin (bevacizumab) + Torisel (temsirolimus) versus Sutent (sunitinib) versus Avastin+ Roféron(interfé... 2012-01-13 due-trials
Reported results 2007-007968-19 Evaluation comparative, en double aveugle, de l'efficacité d'infiltrations locales per et post opératoires de ropivacaïne dans la prise en charge de la douleur après chirurgie hépatique chez l'adulte 2014-02-17 due-trials
Reported results 2008-002138-31 Evaluation de l'efficacité, de la tolérance et analyse médico-économique d'une administration unique de Pegfilgrastim dans les Autogreffes de cellules souches périphériques chez des patients atteints ... 2010-01-31 due-trials
Reported results 2009-009867-70 Evaluation, chez des femmes atteintes d’un cancer du sein non métastatique recevant un traitement antihormonal adjuvant, de l’efficacité d’un traitement homéopathique par BRN-01 versus placebo dans le... 2014-04-10 due-trials
Reported results 2009-009899-12 Evaluation chez l’enfant et l’adulte présentant une rechute d’ostéosarcome de l’efficacité et de la tolérance d’un traitement adjuvant par Thiotépa® haute dose associé à une chimiothérapie conventionn... 2018-10-17 due-trials
Reported results 2009-011280-37 Efficacy and safety assessment of oral LBH589 in adult patients with advanced soft tissue sarcoma after doxorubicin failure: an open-label, multi-centric phase II study 2012-09-27 due-trials
Reported results 2010-018869-29 PHASE II STUDY OF NILOTINIB EFFICACY IN PIGMENTED VILLO-NODULAR SYNOVITIS/ TENOSYNOVIAL GIANT CELL TUMOUR (PVNS/TGCT) 2013-10-04 due-trials
Completed, but no date, and reported results 2010-023265-22 A randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy of afatinib (BIBW 2992) in maintenance therapy after postoperative concurrent radiotherapy and chemotherapy for... bad-data
No trial status on register, and reported results 2010-023461-22 Efficacité et tolérance d’emplâtres de lidocaïne à 5% (Versatis® 5%) dans les douleurs neuropathiques et dans les douleurs de crises vaso-occlusives drépanocytaires de l’enfant, de l’adolescent et du ... bad-data
Exempt, with results 2011-003372-37 An international, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presen... 2019-03-04 not-yet-due
Reported results 2012-002403-18 PIK-ORL: A Phase II, multicenter trial aiming to evaluate BKM120 in monotherapy in patients with metastatic head and neck cancer recurrent or progressive under platin and cetuximab-based chemotherapy ... 2019-01-31 due-trials
Reported results 2012-003162-41 A randomized, multicenter, open-label, phase II study of the optimal scheme of administration of pazopanib in thyroid carcinoma Etude de phase II randomisée, multicentrique, en ouvert, du schema d'... 2019-07-10 due-trials
Reported results 2013-000076-16 BENEFIT - A multicenter phase II study evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) prior to autologous stem cell transplant for first and second chemosensitive relapses in patien... 2018-10-08 due-trials
Completed, report not yet due 2013-001372-37 A randomized, multicentre, phase III trial evaluating the interest of imatinib treatment maintenance or interruption after 3 years of adjuvant treatment in patients with Gastrointestinal Stromal Tumou... 2023-12-07 not-yet-due
Other 2013-002766-39 An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma. Ένα διεθνές κλινικό πρόγραμμα για τη διάγνωση και τη θεραπεία παιδιών, ε... not-yet-due
Ongoing 2013-004039-60 A multicenter study to evaluate a risk-adapted strategy for treatment of extra cranial non seminomateous malignant germ cell tumour in children, adolescent and young adult Etude multicentrique éval... not-yet-due
Completed, but no date, and reported results 2016-002736-33 CHEMOIMMUNE - A Phase II study evaluating an anti-PD1 monoclonal antibody (pembrolizumab) in lymphopenic metastatic breast cancer patients treated with metronomic cyclophosphamide CHEMOIMMUNE - Et... bad-data
Completed, but no date 2016-004537-25 An Phase II trial aiming to evaluate the clinical interest of ABEMACICLIB monotherapy in patients with locally advanced/metastatic head and neck cancer after failure of platinum and cetuximab or anti-... bad-data
Other 2016-005019-42 A European, multicenter, randomized, open-label, Phase II trial aiming to assess the clinical and biological activity of an anti-PD-L1 (atezolizumab) in operable localized soft tissue sarcomas patient... not-yet-due
Other 2017-002069-22 BREASTIMMUNE02 - A multicenter, randomized, open-label, Phase II trial aiming to evaluate the impact of pegfilgrastim on trastuzumab anti-tumor effect and antibody-dependent cell-mediated cytotoxicity... not-yet-due
Completed, but no date 2017-003151-34 A multicenter, randomised, open-label Phase II study to evaluate the clinical benefit of a post-operative treatment associating radiotherapy + Nivolumab + Ipilimumab versus radiotherapy + Capecitabine... bad-data
Completed, report not yet due 2018-000414-38 Frail-Immune (GORTEC-2018-03) - A multicenter, prospective, single arm phase II study evaluating the efficacy and safety of the combination of Durvalumab with carboplatin and paclitaxel as first line ... 2024-03-09 not-yet-due
Other 2018-001789-41 Trial Of Imatinib After Ponatinib Induction (Tipi) - A multicentre, open label phase II trial evaluating the safety and efficacy of ponatinib induction followed by imatinib maintenance in adult patien... not-yet-due
Reported results Terminated 2018-003994-80 A Phase II study evaluating AGuIX® nanoparticles in combination with Stereotactic Radiation for oligo brain metastases Etude de phase II évaluant les nanoparticules AGUIX® en combinaison avec la ra... 2021-02-22 due-trials
Other 2018-004045-16 REGOSTA – A randomized, placebo-controlled, double-blinded, multicentre study evaluating the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bone ... not-yet-due
Other 2018-004332-30 LENVAGIST - A multicentre, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imatinib... not-yet-due
Other 2019-000678-41 CABRAMET - A phase 2 study of cabozantinib in renal cell carcinoma (mRCC) with brain metastases CABRAMET - Etude de phase 2 évaluant le cabozantinib dans le traitement du carcinome à cellules rénal... not-yet-due
Exempt 2019-000987-80 COTESARC - A multicentre Phase I-II study evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advanced and/or metastatic soft tissue sarcoma... not-yet-due
Other 2019-001494-88 MegaMOST - A multicenter, open-label, biology driven, Phase II study evaluating the activity of anti-cancer treatments targeting tumor molecular alterations/characteristics in advanced / metastatic tu... not-yet-due
Other 2019-001547-43 ATEZOGIST – A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib resumption alone in patients with unresectable a... not-yet-due
Reported results 2019-001711-23 CICA-RT – Phase III randomized multicenter study evaluating Cicaderma® ointment efficacy versus the current practice of each center for the radiation dermatitis prevention in patients with non-metasta... 2021-07-01 due-trials
Other 2019-002629-31 REGOMAIN – A randomized, placebo-controlled, double-blinded, multicentre, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients with high grade bone sarcomas (... not-yet-due
Ongoing 2019-003346-32 PREFAcE : Interest of PET-PSMA imaging potentiated by androgen blockade in patients with biological relapse or persistent biological disease of a localized prostatic adenocarcinoma after initial treat... not-yet-due
Reported results Terminated 2020-001373-70 IMMUNONCOVID-20 : A prospective, controlled, randomized, multicenter study to compare the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab... 2021-07-06 due-trials
Other 2020-002821-28 RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma of r... not-yet-due
Other 2020-004957-62 Immunotherapy in MSI/dMMR Tumors in perioperative setting Immunothérapie en péri-opératoire dans les tumeurs MSI/dMMR not-yet-due
Ongoing, reported early 2021-000571-37 A multicenter, randomized, open-label phase II trial evaluating the association of Gadolinium-based nanoparticles (AGuIX®) with radiotherapy for the therapeutic management of patients with progressive... not-yet-due
Other 2021-001065-21 PAXIPEM - Multicenter phase II study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC) PAXIPEM - Etude de ... not-yet-due
Other 2021-001430-19 GIST-TEN: Randomized, prospective, multicentre, open label phase II study evaluating the interest of imatinib (Glivec) treatment maintenance or interruption after at least 10 years of treatment in pat... not-yet-due
Ongoing 2021-003042-20 PARPi-PANC - A multicentric, single arm, phase II trial assessing the efficacy of niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer PARPi-PA... not-yet-due